Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT06935357) titled 'A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)' on April 17.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Biogen
Condition:
Immunoglobulin A Nephropathy (IgAN)
Intervention:
Drug: Felzartamab
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: May 8, 2025
Target Sample Size: 454
Countries of Recruitment:
United States
Argentina
China
J...